Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
CA 2362338 A1 · Owner: Tuttle, Robert C. · Inventors: Kadima, Tenshuk A.; Tuttle, Robert C.; Hegedus, Lajos
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An optically clear, pharmaceutically acceptable aqueous composition comprising paclitaxel or a derivative thereof, serum albumin and a pharmaceutically acceptable vehicle, wherein the composition comprises no more than 10 % organic solvent and has a pH of about 3.0 to about 4.8 is described. The , serum albumin can be fatted or defatted and the composition can optionally be lyophilized or optionally lyophilized and reconstituted. At least 70 % of the paclitaxel is bound to serum albumin, the ratio of paclitaxel to albumin is at least about 1:5, and the concentration of paclitaxel is at least about 25 µg/ml. Methods of making and using this composition are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 29, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 29, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 29, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.